Capricor Therapeutics (CAPR) Return on Capital Employed (2016 - 2025)
Historic Return on Capital Employed for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to 0.73%.
- Capricor Therapeutics' Return on Capital Employed rose 700.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.45% for FY2024, which is 5900.0% up from last year.
- Per Capricor Therapeutics' latest filing, its Return on Capital Employed stood at 0.73% for Q3 2025, which was up 700.0% from 0.52% recorded in Q2 2025.
- Capricor Therapeutics' 5-year Return on Capital Employed high stood at 0.38% for Q4 2024, and its period low was 3.57% during Q3 2023.
- In the last 5 years, Capricor Therapeutics' Return on Capital Employed had a median value of 0.77% in 2024 and averaged 1.09%.
- As far as peak fluctuations go, Capricor Therapeutics' Return on Capital Employed tumbled by -28900bps in 2023, and later skyrocketed by 27700bps in 2024.
- Capricor Therapeutics' Return on Capital Employed (Quarter) stood at 0.55% in 2021, then plummeted by -61bps to 0.89% in 2022, then tumbled by -63bps to 1.44% in 2023, then soared by 73bps to 0.38% in 2024, then tumbled by -91bps to 0.73% in 2025.
- Its last three reported values are 0.73% in Q3 2025, 0.52% for Q2 2025, and 0.38% during Q4 2024.